Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selective laser trabeculoplasty versus eye drops for first line treatment of exfoliation ocular hypertension or glaucoma
2024-520083-33-00Phase 4Authorised
- Sponsor
- Helsinki University Hospital
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tafluprost in Glaucoma and ocular hypertension (2 arms), sponsored by Helsinki University Hospital. Primary endpoint: Acceleration of treatment by adding eye drops. Planned start Dec 2024; status: authorised.
02
Drugs
tafluprost
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on 2024-520083-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520083-33-00.